These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 24741024)
21. Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer. Szarvas T; Csizmarik A; Fazekas T; Hüttl A; Nyirády P; Hadaschik B; Grünwald V; Püllen L; Jurányi Z; Kocsis Z; Shariat SF; Sevcenco S; Maj-Hes A; Kramer G BJU Int; 2021 Jan; 127(1):44-55. PubMed ID: 32314509 [TBL] [Abstract][Full Text] [Related]
22. Implications of circulating chromogranin A in prostate cancer. Hirano D; Minei S; Sugimoto S; Yamaguchi K; Yoshikawa T; Hachiya T; Kawata N; Yoshida T; Takahashi S Scand J Urol Nephrol; 2007; 41(4):297-301. PubMed ID: 17763220 [TBL] [Abstract][Full Text] [Related]
23. [Serum alkaline phosphatase flare in prostate cancer accompanied by bone metastases and treated with hormonal therapy. TEKK Study Group]. Taue R; Kanayama H; Kagawa S Hinyokika Kiyo; 1999 Oct; 45(10):681-5. PubMed ID: 10586358 [TBL] [Abstract][Full Text] [Related]
24. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer. Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278 [TBL] [Abstract][Full Text] [Related]
25. Serum levels of chromogranin A are not predictive of high-grade, poorly differentiated prostate cancer: results from an Italian biopsy cohort. De Nunzio C; Albisinni S; Presicce F; Lombardo R; Cancrini F; Tubaro A Urol Oncol; 2014 Feb; 32(2):80-4. PubMed ID: 23153859 [TBL] [Abstract][Full Text] [Related]
26. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls. Marszalek M; Wachter J; Ponholzer A; Leitha T; Rauchenwald M; Madersbacher S Eur Urol; 2005 Jul; 48(1):34-9. PubMed ID: 15967249 [TBL] [Abstract][Full Text] [Related]
27. Prospective study on the relationship between clinical efficacy of secondary hormone therapy with flutamide and neuroendocrine differentiation in patients with relapsed prostate cancer after first line hormone therapy. Hirano D; Hasegawa R; Satoh K; Mochida J; Yamanaka Y; Hirakata H; Yamaguchi K; Sugimoto S; Kawata N; Takahashi S Scand J Urol; 2014 Oct; 48(5):436-44. PubMed ID: 24730473 [TBL] [Abstract][Full Text] [Related]
28. Elevated serum chromogranin A precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced prostate cancer. Chuang CK; Wu TL; Tsao KC; Liao SK J Formos Med Assoc; 2003 Jul; 102(7):480-5. PubMed ID: 14517586 [TBL] [Abstract][Full Text] [Related]
29. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Italiano A; Ortholan C; Oudard S; Pouessel D; Gravis G; Beuzeboc P; Bompas E; Fléchon A; Joly F; Ferrero JM; Fizazi K Eur Urol; 2009 Jun; 55(6):1368-75. PubMed ID: 18706755 [TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Taplin ME; George DJ; Halabi S; Sanford B; Febbo PG; Hennessy KT; Mihos CG; Vogelzang NJ; Small EJ; Kantoff PW Urology; 2005 Aug; 66(2):386-91. PubMed ID: 16098367 [TBL] [Abstract][Full Text] [Related]
31. Treatment outcome of docetaxel plus prednisolone for metastatic castration-resistant prostate cancer in Korea. Cho IC; Joung JY; Seo HK; Chung J; Park WS; Lee KH J Cancer Res Ther; 2014; 10(2):251-7. PubMed ID: 25022374 [TBL] [Abstract][Full Text] [Related]
32. Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole. Leibowitz-Amit R; Seah JA; Atenafu EG; Templeton AJ; Vera-Badillo FE; Alimohamed N; Knox JJ; Tannock IF; Sridhar SS; Joshua AM Eur J Cancer; 2014 Sep; 50(14):2399-407. PubMed ID: 25042152 [TBL] [Abstract][Full Text] [Related]
33. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer. Miyake H; Sakai I; Terakawa T; Harada K; Fujisawa M Urol Oncol; 2013 Aug; 31(6):733-8. PubMed ID: 21782481 [TBL] [Abstract][Full Text] [Related]
34. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Sciarra A; Monti S; Gentile V; Mariotti G; Cardi A; Voria G; Lucera R; Di Silverio F Prostate; 2003 May; 55(3):168-79. PubMed ID: 12692782 [TBL] [Abstract][Full Text] [Related]
35. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients. Sasaki T; Komiya A; Suzuki H; Shimbo M; Ueda T; Akakura K; Ichikawa T Eur Urol; 2005 Aug; 48(2):224-9; discussion 229-30. PubMed ID: 16005374 [TBL] [Abstract][Full Text] [Related]
36. Correlation between age and Chromogranin A determination in prostate diseases. Mearini L; Zucchi A; Scarponi E; Nunzi E; Aglietti MC; Bini V; Porena M Cancer Biomark; 2011-2012; 10(3-4):117-23. PubMed ID: 22674297 [TBL] [Abstract][Full Text] [Related]
37. The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study. Mahammedi H; Planchat E; Pouget M; Durando X; Curé H; Guy L; Van-Praagh I; Savareux L; Atger M; Bayet-Robert M; Gadea E; Abrial C; Thivat E; Chollet P; Eymard JC Oncology; 2016; 90(2):69-78. PubMed ID: 26771576 [TBL] [Abstract][Full Text] [Related]
38. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer. Heck MM; Thalgott M; Retz M; Wolf P; Maurer T; Nawroth R; Hatzichristodoulou G; Gschwend JE; Kübler H BJU Int; 2012 Dec; 110(11 Pt B):E635-40. PubMed ID: 22889368 [TBL] [Abstract][Full Text] [Related]
39. Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A. Sciarra A; Voria G; Monti S; Mazzone L; Mariotti G; Pozza M; D'Eramo G; Silverio FD Prostate; 2004 Mar; 58(4):421-8. PubMed ID: 14968443 [TBL] [Abstract][Full Text] [Related]
40. Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia. Sciarra A; Gentile V; Monti S; Dattilo C; Autran Gomez A; Salciccia S; Pannunzi LP; Toscano V; Di Silverio F Urol Int; 2008; 80(1):68-73. PubMed ID: 18204237 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]